At a time when partisanship in Congress appears to be at an all-time high, the agencies I primarily cover—NIH and FDA— appear to be faring pretty well (I am in no way implying this is because of me, but if you’d like to think I actually have that much power, who am I to impede such misguided thoughts?).
The National Institutes of Health just came out strong in the last funding cycle, as congressional appropriators secured a $3 billion increase for the agency—the largest in at least 15 years. The Food and Drug Administration also got a more than $130 million increase above last year. The heads of both agencies clearly garnered the respect of lawmakers from both parties, which I’ve witnessed firsthand at a checkup of the 21st Century Cures law and other events.
But while money talks—and it definitely does—lawmakers also seem to be following through on Francis Collins’s and Scott Gottlieb’s requests for how to do things like combat the opioid crisis. Collins asked the Senate health committee to give the NIH what’s known as the “other transactions authority,” to accelerate research on combating a crisis that takes more than 115 lives a day.
“We could really use this now in the opioid crisis,” he told the Senate health committee back in December.
Almost exactly two months later, the heads of that committee, Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.), introduced a bill to do exactly that. Reps. Debbie Dingell (D-Mich.) and Fred Upton (R-Mich.) followed up less than a week later for a version in the House Energy and Commerce Committee.
Meanwhile, Gottlieb has been saying forever (or at least since he’s been talking about the opioid crisis as the FDA commissioner) that he wants to look into blister packs for opioids, which he said could encourage doctors to write shorter-term prescriptions and potentially curb new addictions. He said this in October; he said it again in January; I heard him say it at an Alliance for a Stronger FDA event in February; and he’s probably said it a bunch more times. I think you get the point.
Anyway, a few days ago, Sen. Alexander announced draft legislation to allow the FDA to require blister packs for opioids. Likewise, Energy and Commerce members Richard Hudson (R-N.C.) and G.K. Butterfield (D-N.C.) are also working on a draft version.
You can read the story about the blister pack legislation here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)